cancer surgeon trained at MD Anderson and John Wayne Cancer Institute. Now practicing in Dallas. Specializing in breast cancer and melanoma
Dallas
Joined March 2009
- Tweets924
- Following1.8K
- Followers1.9K
- Likes209
Bring back the Mens Wool Lounger in Kereru Moonstone. (Who doesn’t love Moonstone?). They are a great color and super comfortable. @Allbirds
Peter Beitsch retweeted
NEWS ALERT: Aptitude Health Acquires TME BCN. The company will expand into the oncology breast surgery space and accelerate the growth of its physician network:
tmebcn.com/aptitude-health-a…
Peter Beitsch retweeted
@ness_atn great article
I’ve had similar condition since birth like Cam. Let’s get better treatment🦋@LymphedemaAct @MsKathyBates
people.com/health/cam-ayala-…
Peter Beitsch retweeted
What happens in Vegas…..@ASBrS22 @IronwoodCancer. I love my partners and am excited for these future breast surgeons at the American Society of Breast Surgeons meeting. So good to be together!
Peter Beitsch retweeted
For all of you wanting to know where Dr. Beitsch got his 💕pink blazer… he was inspired by @JohnnyGWeir and it is by @RalphLauren
#ASBrS22 Fashion
Peter Beitsch retweeted
Just in case you thought only med oncs like @drdonsdizon could rock the pink blazer… #asbrs22
New portable scalp cooling system to mitigate chemotherapy related hair loss!
Cooler Heads - One Minute Video Competition youtu.be/fA9Hh0WBI5M via @YouTube
Bob Sturm -Drop Your Pants 8 - September 14, 2021 gofund.me/83ee832b
‘Aggressive prostate cancer’ is a subjective term, Gleason score is judged by humans - 6 not aggressive and 7 is aggressive.... Isn’t it time to germline test all prostate cancer patients? All cancer patients? #freeTheDNA @DrRakeshPatel @md_rosen @WhitworthMD @NoelPugh
It’s estimated that 13% of men in the U.S. will develop prostate #cancer within their lifetime.
Recently updated #NCCN guidelines recommend that all men with aggressive #prostatecancer consider #genetictesting, regardless of family history. Learn more: ow.ly/nZG550EO03c
The emperor (NCCN) is still naked - guidelines to decide which cancer patients need germline genetic testing DO NOT WORK & harm patients AND THEIR FAMILIES! It is time to pressure the @NCCN to change their antiquated economic road blocks (guidelines). #FreetheDNA @DrRakeshPatel
New @MayoClinic study finds that 1 in 6 patients with #colorectalcancer had an inherited cancer-related gene mutation, which likely predisposed them to the disease. Researchers also discovered that 60% of cases would not have been detected with a standard guideline-based approach
Peter Beitsch retweeted
Genomicists & clinicians are beginning to offer patients #genomictesting for a list of treatable diseases apart from the one that brought them into the clinic. Learn about the role secondary findings play in diagnosing #diseases & saving lives:
ow.ly/OzOg50EO02i
Any 'guideline' excluding some breast cancer pts will miss pts with pathogenic mutations! I'm truly perplexed at the reticence to test ALL breast cancer pts. Yes there will be PV's w few management guidelines & VUS's (don't act on these)- it's OK we can handle these minor issues
In her new blog, Maureen Graham explores the big question: Would expansion of the #NCCNGuidelines - rather than universal testing of all women with #breastcancer - be a reasonable compromise for detection of inherited #cancer susceptibility? More here: blog.medneon.com/a-happy-med…
Peter Beitsch retweeted
At Medneon, our #mission is to empower individuals and their care team to get ahead of life-threatening disease.
Learn how this little pup named Polly represents Medneon’s big mission, from our very own Kelly Bontempo: blog.medneon.com/meet-polly/ #RiskAssessment #GeneticInsights
Peter Beitsch retweeted
At Medneon, we’re on a mission to prevent cancer, and we believe that information and insights have the power to do so.
That’s why today, we’re delighted to launch the Medneon #blog, a place for #doctors, #genetics experts, #data scientists, and #technologists to explore…
Peter Beitsch retweeted
Direct-to-consumer #genetictests use SNP genotyping to identify common variants in the general population — but exactly how accurate are they in identifying rare mutations?
Results from a recent study published in #theBMJ suggest SNP chips are “the wrong tool for the job.”
Peter Beitsch retweeted
...with solid tumors were positive for pathogenic or likely pathogenic variants in dominant & recessive cancer predisposition #genes when including all levels of penetrance. The author recommends germline testing be considered for ALL children with cancer: clinicalomics.com/topics/onc…
Peter Beitsch retweeted
“Think of it this way: When your doctor orders genetic testing, it’s akin to fishing for a particular fish, in a part of the ocean where it’s known to live. A DTC test is more like throwing a net into the ocean and seeing what comes back.”
More here: consumerreports.org/genetic-…
Peter Beitsch retweeted
A new @ConsumerReports article details the limitations - and possible dangers - of direct-to-consumer #genetictesting.
When it comes to assessing #geneticrisk, experts advise relying on #healthcare providers and #geneticcounselors.
Peter Beitsch retweeted
Big news: Medneon’s tools are being added to @Invitae's education and clinical support offerings.
These additions will make it easier for #clinicians to use #genetics to improve #patientcare. Learn more: ow.ly/YDNc50DJOIs #riskassessment #precisionhealth
